Transgender hormone therapy (male-to-female) medical professional. Inducers of CYP3A4 and other cytochrome P450 enzymes can reduce the effects of MTF HRT. A variety of different sex-hormonal medications are used in feminizing hormone therapy for transgender women. These include estrogens to induce feminization and suppress testosterone levels; antiandrogens such as androgen receptor antagonists, antigonadotropins, GnRH modulators, and 5α-reductase inhibitors to further oppose the effects of androgens like testosterone; and progestogens for various possible though uncertain benefits. Estrogens are the major sex hormones in women, and are responsible for the development and maintenance of feminine secondary sexual characteristics, such as breasts, wide hips, and a feminine
Biology and sexual orientation male sexual orientation. The research consisted of 1,077 homosexual men and 1,231 heterosexual men. A gene named SLITRK6 on chromosome 13 was identified, and contains an area or DNA sequence which is different for gay men than for heterosexual men. The research supports another study which had been done by Simon levay. Levay's research suggested that the hypothalamus of gay men is different from straight men. The SLITRK6 is active in the mid-brain where the hypothalamus is. The researchers found another gene, named "thyroid stimulating hormone receptor" (TSHR) on chromosome 14 which dna sequence is different also for gay men.